SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Verastem, Inc. (VSTM) News

Follow Verastem, Inc. (VSTM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 23 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol VSTM Asset equity Sector Markets 90 days 19 Last 6.335 Updated Nov 05, 2026, 09:47 PM UTC Open live news feed Open VSTM chart & news
M Verastem Reports $24 Million in Q3 Product Revenue, Cash Runway Into 1H 2028 Verastem’s updated corporate presentation reports $24 million in third-quarter product revenue and pro forma cash expected to fund operations into the first half of 2028. EQUITY | Nov 05, 2026, 09:47 PM UTC L BRIEF-Verastem Q3 Operating Expenses USD 99.236 Million Nov 05 (Reuters) - Verastem Q3 net income USD -74.723 million. EARNINGS | Nov 05, 2026, 09:04 PM UTC M Verastem Oncology Q3 Product Revenue Rose to $24.0M Third-quarter net product revenue was $24.0 million, up from $11.2 million in the year-earlier quarter. GAAP net loss was $74.7 million, or $0.74 per share, versus $98.5 million, or $1.35 per share, a year earlier. EQUITY | Nov 05, 2026, 09:01 PM UTC M Verastem Oncology Reports Third-Quarter 2026 Financial Results Verastem Oncology reported financial results for the quarter ended September 30, 2026. The supplied body is truncated and provides no results figures. EQUITY | Nov 05, 2026, 09:01 PM UTC L Verastem 3Q Loss/Shr 74c >VSTM Verastem 3Q Loss/Shr 74c >VSTM EQUITY | Nov 05, 2026, 09:01 PM UTC L Verastem 3Q Rev $24M >VSTM Verastem 3Q Rev $24M >VSTM EQUITY | Nov 05, 2026, 09:01 PM UTC M Verastem shares jump 20% after positive cancer drug trial update Verastem Oncology shares rose 20% Thursday, their best day since November 2025, after a positive update on experimental drug VS-7375 in second-line metastatic pancreatic ductal adenocarcinoma. Analysts also lifted price EQUITY | Oct 15, 2026, 09:00 PM UTC M Verastem Reports Positive Initial Trial Data and Prices Offering Verastem Oncology said its in-development tumor treatment VS-7375 showed clinical activity and a favorable safety and tolerability profile across multiple dose levels and tumor types. The company also priced an underwrit EQUITY | Oct 14, 2026, 10:52 AM UTC L VSTM reports VS-7375 cancer-trial response results The company reports 50% confirmed overall response rate in second-line pancreatic ductal adenocarcinoma and two complete responses in second-line-or-later disease. EQUITY | Oct 14, 2026, 10:01 AM UTC H BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday U.S. stocks were lower, with the Dow Jones index falling around 1% on Wednesday. Shares of BKV Corp (NYSE: BKV ) rose sharply after the company announced that a subsidiary executed into a n equipment supply contract. BKV LIVE | Oct 07, 2026, 02:08 PM UTC L Verastem Oncology Posts 2-Year Follow-Up Data From RAMP 201 Verastem Oncology reported two-year median follow-up results from Phase 2 RAMP 201 in recurrent LGSOC, showing durable efficacy and no new safety signals, including an increase in median DoR for KRAS wild-type patients f NEWS | Sep 28, 2026, 08:10 PM UTC L Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Gynecologic Oncology, the official journal of the NEWS | Sep 28, 2026, 08:10 PM UTC H Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that an abstract about molecular profiling and tumor b NEWS | Sep 24, 2026, 12:30 PM UTC L VSTM: Advancing RAS/MAPK therapies with pivotal trials and new data to expand cancer treatment options The session highlighted progress in commercial and clinical programs for RAS/MAPK-driven therapies, including a strong launch for the CO-PACK in ovarian cancer and advancing VS-7375 in multiple tumor types. Key upcoming NEWS | Sep 14, 2026, 07:29 PM UTC L VSTM: Advancing selective KRAS therapies with robust clinical progress and upcoming pivotal data The session highlighted strong commercial and clinical progress for a KRAS-mutated ovarian cancer therapy and the advancement of a selective KRAS G12D inhibitor across multiple tumor types. Upcoming data readouts and new NEWS | Sep 14, 2026, 07:01 PM UTC L VSTM: Pivotal G12D inhibitor data and commercial momentum drive expansion and strategic partnerships Key updates include strong progress in the G12D inhibitor program with pivotal data expected in October, robust commercial growth for avutometinib/defactinib, and strategic plans for phase III trials and partnerships. Th EQUITY | Sep 10, 2026, 02:00 PM UTC L VSTM: Major data update for G12D inhibitor set for October, with phase III trials and partnerships ahead Significant clinical progress was highlighted for the G12D inhibitor, with major data updates expected in October and phase III trials planned for next year. The drug is positioned as best-in-class, with strong efficacy, EQUITY | Sep 10, 2026, 01:34 PM UTC L Verastem Oncology to host Oct. 14 investor event for VS-7375 data Verastem Oncology said it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor. EQUITY | Sep 08, 2026, 11:30 AM UTC L Verastem Oncology to participate in Sept. 8 investor conference Verastem Oncology said its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston. EQUITY | Sep 02, 2026, 11:30 AM UTC L VSTM Verastem Oncology doses first patient in target-d 203 phase 2 registration-directed trial of vs-7375 oral kras g12d (on/off) inhibitor VSTM Verastem Oncology doses first patient in target-d 203 phase 2 registration-directed trial of vs-7375 oral kras g12d (on/off) inhibitor for kras g12d-mutated metastatic colorectal cancer EQUITY | Jul 28, 2026, 08:01 PM UTC H Verastem price target lowered to $14 from $15 at RBC Capital RBC Capital lowered the firm's price target on Verastem to $14 from $15 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up EQUITY | Jul 07, 2026, 11:32 AM UTC H VSTM: Reports Encouraging VS-7375 Data Verastem Oncology reports encouraging clinical activity and favorable safety profile for VS-7375 in Phase 1/2 clinical study EQUITY | Jun 23, 2026, 08:05 PM UTC H VSTM Shows Promise VSTM's VS-7375 demonstrates clinical activity with favorable safety in Phase 1/2 trial for KRAS G12D-mutated solid tumors EQUITY | Jun 23, 2026, 08:01 PM UTC